Download Full Text (13.5 MB)
The utilization of T-cell immunotherapy stands as a promising strategy to addressing various ailments, most notably cancer, by leveraging endogenous T cells or genetically modified T cells. The augmentation of therapeutic T cells ex vivo remains a pivotal juncture within the manufacturing process that is inevitable for attainment of ample cell quantities. The enhancement of the enduring presence of the transplanted therapeutic T cells remains of paramount significance for favorable results. This research delves into the plausibility of amplifying human T cells while preventing undue differentiation through the employment of microbeads veneered with an innovative peptide ligand that targets CD3𝜀 (WSLGYTG). The isolation of human pan T cells from the PBMCs of healthy donors ensued via the EasySep Human Pan T Cell Isolation Kit. The proliferation ofT cell was induced by the use of microbeads conjugated with the peptide ligand, juxtaposed against a control group employing the current industry gold standard, DynabeadsⓇ Human T-Activator CD3/CD28. Evident in the experimental group was heightened cell amplification and a mitigated propensity for displaying CD45RO, a marker for more differentiated T cell phenotypes, compared to the control group. These encouraging preliminary findings insinuate the potential of microbeads embellished with the innovative peptide ligand in facilitating the expansion of therapeutic T cells tailored for immunotherapeutic pursuits. Further scrutiny is imperative to optimize and exploit this methodology in the realm of more efficacious T-cell immunotherapies.
Research and Creative Experience for Undergraduates (RCEU)
Chemical and Materials Engineering
College of Engineering
Immunotherapy, microbeads, peptide ligand, T cell Phenotypes
Rolin, Jacob, "Expansion of T Cells Using Microbeads Coated with Novel Peptide Ligand against CD3" (2023). Summer Community of Scholars Posters (RCEU and HCR Combined Programs). 434.